ERGO (Entia Biosciences) Equity-to-Asset: -4.48 (As of Dec. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Entia Biosciences Equity-to-Asset?

Entia Biosciences ERGO Equity-to-Asset is -4.48 as of Dec. 2016.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Entia Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2016 was $-1.97 Mil. Entia Biosciences's Total Assets for the quarter that ended in Dec. 2016 was $0.44 Mil. Therefore, Entia Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2016 was -4.48.

The historical rank and industry rank for Entia Biosciences's Equity-to-Asset or its related term are showing as below:

ERGO's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.69
* Ranked among companies with meaningful Equity-to-Asset only.

Entia Biosciences  (OTCPK:ERGO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Entia Biosciences Equity-to-Asset Related Terms

Entia Biosciences Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for Entia Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entia Biosciences Equity-to-Asset Chart

Entia Biosciences Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only -1.17 -1.32 -0.13 -1.76 -4.48

Entia Biosciences Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.76 -2.53 -3.48 -4.49 -4.48

ERGO vs OBMP, NSPX, ATRX: Equity-to-Asset Comparison

For the Biotechnology subindustry, Entia Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entia Biosciences Equity-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entia Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Entia Biosciences's Equity-to-Asset falls into.


Entia Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Entia Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Equity to Asset (A: Dec. 2016 )=Total Stockholders Equity/Total Assets
=-1.966561/0.439141
=-4.48

Entia Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2016 is calculated as

Equity to Asset (Q: Dec. 2016 )=Total Stockholders Equity/Total Assets
=-1.966561/0.439141
=-4.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of -4.48 mean?
Entia Biosciences (ERGO) has a Equity-to-Asset of -4.48 as of Dec. 2016. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Entia Biosciences and its competitors.
Is Entia Biosciences' Equity-to-Asset too high?
Entia Biosciences' current Equity-to-Asset is -4.48.
How does Entia Biosciences' Equity-to-Asset compare to OBMP and NSPX?
Entia Biosciences' Equity-to-Asset of -4.48 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Entia Biosciences and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entia Biosciences's current Equity-to-Asset is -4.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entia Biosciences stock overvalued right now?
Entia Biosciences (ERGO) has a current Equity-to-Asset of -4.48. The current Equity-to-Asset is -4.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Entia Biosciences (ERGO), the current Equity-to-Asset is -4.48 as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entia Biosciences Business Description

Address 13565 South West Tualatin-Sherwood Road, Suite 800, Sherwood, OR, USA, 97140
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.